Contents of the label
Betahistina dihidrocloruro
Betahistina is used for the treatment of Meniere's Syndrome, which is a disorder characterized by the following symptoms: vertigo (with nausea and vomiting), hearing loss, and a sensation of noise inside the ear (tinnitus).
The active ingredient of this medication is a histamine analogue that acts by improving circulation in the inner ear and thereby reducing pressure. The inner ear is one of the organs responsible for the sense of balance.
Do not take Betahistina Normon
Consult your doctor or pharmacist before starting to take betahistina:
Inform your doctor or pharmacist if you are using, have used recently or may need to take any other medication, including those purchased without a prescription.
The administration at the same time as Betahistina Normon with antiallergic medications such as antihistamines (especially H1 antagonists) may reduce the effectiveness of both medications.
The administration at the same time as Betahistina Normon with monoamine oxidase inhibitors (MAOIs), (used for the treatment of Parkinson's disease), may increase the effect of Betahistina Normon.
It is recommended to take Betahistina Normon during or after meals to avoid gastrointestinal discomfort.
Children and Adolescents
Betahistina Normon is not recommended for use in children and adolescents under 18 years of age due to the lack of experience in these age groups.
If you are pregnant or breastfeeding, think you may be pregnant or intend to become pregnant, consult your doctor or pharmacist before using this medication.
The effects of this medication on the fetus are unknown, so Betahistina Normon should not be taken during pregnancy, unless your doctor considers it necessary.
The effects of this medication on breast milk are unknown, so if you are taking Betahistina Normon, do not breastfeed your child.
Betahistina is indicated for Meniere's syndrome. This disease may negatively affect the ability to drive and operate machines. In clinical trials specifically designed to investigate the ability to drive or operate machines, betahistina had no effects or were insignificant.
Your doctor will adjust the dose based on your response to treatment, starting from an initial dose of 1 tablet of 8 mg three times a day up to two tablets of 8 mg three times a day (maximum dose). The maintenance dose will be adjusted based on your response, with the minimum effective dose being one tablet of 8 mg three times a day.
The tablets should be taken with water.
In some cases, improvement may not become apparent until two weeks after starting treatment. The best results are obtained after several months of treatment.
The tablets can be taken with or without food. However, if taken without food, they may cause mild stomach problems (listed in section 4). Taking the tablets with food may help reduce stomach problems.
Betahistina is not recommended for use in children and adolescents under 18 years due to a lack of data on safety and efficacy.
In case of overdose or accidental ingestion, consult your doctor or pharmacist immediately or call the Toxicology Information Service at 91.562.04.20, indicating the medication and the amount ingested.
You may experience the following symptoms due to an overdose: nausea, drowsiness, abdominal pain. You may also experience rapid heartbeat (tachycardia), low blood pressure (hypotension), difficulty breathing with a sensation of choking (bronchospasm), fluid accumulation in tissues (edema). Seizures may occur after taking very high doses.
It is recommended that you receive symptomatic treatment, as there is no specific antidote.
Do not take a double dose to make up for missed doses. If you forget to take a dose, wait until the next scheduled dose and continue with the regular treatment.
You should take betahistina for as long as your doctor recommends. Do not interrupt treatment prematurely, as this may not produce the expected results.
If you have any other questions about the use of this medication, ask your doctor, pharmacist, or nurse.
The classification by frequencies is as follows:
Very frequent: may affect more than 1 in 10 patients
Frequent: may affect up to 1 in 10 patients |
Infrequent: may affect up to 1 in 100 patients |
Rare: may affect up to 1 in 1,000 patients |
Very rare: may affect up to 1 in 10,000 patients |
Unknown frequency: the frequency cannot be estimated from the available data In clinical trials, the adverse effects found were: |
Gastrointestinal disorders
Frequent: nausea and dyspepsia (discomfort in the upper abdomen with a feeling of bloating).
Nervous system disorders
Frequent: headache.
After its commercialization and in scientific literature, the following adverse effects have been reported with an unknown frequency:
Immune system disorders
Hypersensitivity reactions, for example anaphylaxis.
Gastrointestinal disorders
Mild gastrointestinal discomfort (for example vomiting, gastrointestinal pain, distension, and abdominal bloating). These effects can usually be treated by taking the medication with meals or reducing the dose.
Skin and subcutaneous tissue disorders
Hypersensitivity skin and subcutaneous reactions, particularly angioneurotic edema (skin and mucous membrane swelling, especially on the face, mouth, tongue, and hands), urticaria, skin rash, and pruritus.
If you experience any type of adverse effect, consult your doctor or pharmacist, even if it is a possible adverse effect that does not appear in this prospectus. You can also report them directly through the Spanish System for Pharmacovigilance of Medicinal Products for Human Use: https://www.notificaram.es. By reporting adverse effects, you can contribute to providing more information on the safety of this medication.
Keep this medication out of the sight and reach of children.
This medication does not require special conditions for conservation.
Do not use this medication after the expiration date that appears on the packaging and on the blister pack after CAD.
The expiration date is the last day of the month indicated.
Medications should not be disposed of through drains or in the trash. Dispose of the packaging and medications you no longer need at the SIGRE collection point at the pharmacy. If in doubt, ask your pharmacist how to dispose of the packaging and medications you no longer need. By doing so, you will help protect the environment.
The active ingredient is betahistina dihidrocloruro. Each tablet contains 8 mg of betahistina dihidrocloruro.
The other components (excipients) are: manitol (E-421), celulosa microcristalina, ácido cítrico, hidroxipropilcelulosa de baja sustitución, sílice coloidal, talco and macrogol 6000.
Betahistina Normon 8 mg tablets EFG are presented in the form of white or almost white, round and engraved tablets.
Each package contains 60 tablets.
LABORATORIOS NORMON, S.A.
Ronda de Valdecarrizo, 6 – 28760 Tres Cantos – Madrid (SPAIN)
Other presentations
Betahistina Normon 16 mg tablets EFG
Last review date of this leaflet: June 2024
The detailed information of this medicine is available on the website of the Spanish Agency for Medicines and Medical Devices (AEMPS) http://www.aemps.gob.es/
Have questions about this medication or your symptoms? Connect with a licensed doctor for guidance and personalized care.